BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 22015300)

  • 1. Is gene array testing to be considered routine now?
    Paik S
    Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
    Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
    Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Gene expression based multigene prognostic and predictive tests in breast cancer].
    Pénzváltó Z; Mihály Z; Gyorffy B
    Magy Onkol; 2009 Dec; 53(4):351-9. PubMed ID: 20071307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
    Ross JS
    Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of adjuvant chemotherapy benefit in endocrine responsive, early breast cancer using multigene assays.
    Albain KS; Paik S; van't Veer L
    Breast; 2009 Oct; 18 Suppl 3():S141-5. PubMed ID: 19914534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomics of adjuvant therapy for breast cancer.
    Kim SR; Paik S
    Cancer J; 2011; 17(6):500-4. PubMed ID: 22157294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy in ER+ HER2- breast cancer: response prediction based on immunohistochemical and molecular characteristics.
    Lips EH; Mulder L; de Ronde JJ; Mandjes IA; Vincent A; Vrancken Peeters MT; Nederlof PM; Wesseling J; Rodenhuis S
    Breast Cancer Res Treat; 2012 Feb; 131(3):827-36. PubMed ID: 21472434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Commercialized multigene predictors of clinical outcome for breast cancer.
    Ross JS; Hatzis C; Symmans WF; Pusztai L; Hortobágyi GN
    Oncologist; 2008 May; 13(5):477-93. PubMed ID: 18515733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis.
    Ward S; Scope A; Rafia R; Pandor A; Harnan S; Evans P; Wyld L
    Health Technol Assess; 2013 Oct; 17(44):1-302. PubMed ID: 24088296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
    Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
    Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular predictors of response to therapy for breast cancer.
    Galanina N; Bossuyt V; Harris LN
    Cancer J; 2011; 17(2):96-103. PubMed ID: 21427553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating molecular profiling, histological type and other variables: defining the fingerprint of responsiveness to treatment.
    Viale G
    Breast; 2009 Oct; 18 Suppl 3():S32-6. PubMed ID: 19914539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
    Bianchini G; Iwamoto T; Qi Y; Coutant C; Shiang CY; Wang B; Santarpia L; Valero V; Hortobagyi GN; Symmans WF; Gianni L; Pusztai L
    Cancer Res; 2010 Nov; 70(21):8852-62. PubMed ID: 20959472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling.
    Azim HA; Michiels S; Bedard PL; Singhal SK; Criscitiello C; Ignatiadis M; Haibe-Kains B; Piccart MJ; Sotiriou C; Loi S
    Clin Cancer Res; 2012 Mar; 18(5):1341-51. PubMed ID: 22261811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of molecular subtyping with BluePrint, MammaPrint, and TargetPrint to local clinical subtyping in breast cancer patients.
    Nguyen B; Cusumano PG; Deck K; Kerlin D; Garcia AA; Barone JL; Rivera E; Yao K; de Snoo FA; van den Akker J; Stork-Sloots L; Generali D
    Ann Surg Oncol; 2012 Oct; 19(10):3257-63. PubMed ID: 22965266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is the Oncotype DX assay necessary in strongly estrogen receptor-positive breast cancers?
    Lee JJ; Shen J
    Am Surg; 2011 Oct; 77(10):1364-7. PubMed ID: 22127090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical review of microarray-based prognostic tests and trials in breast cancer.
    Koscielny S
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):47-50. PubMed ID: 18197005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation.
    Karn T; Pusztai L; Ruckhäberle E; Liedtke C; Müller V; Schmidt M; Metzler D; Wang J; Coombes KR; Gätje R; Hanker L; Solbach C; Ahr A; Holtrich U; Rody A; Kaufmann M
    Eur J Cancer; 2012 Jan; 48(1):12-23. PubMed ID: 21741824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients.
    Györffy B; Lanczky A; Eklund AC; Denkert C; Budczies J; Li Q; Szallasi Z
    Breast Cancer Res Treat; 2010 Oct; 123(3):725-31. PubMed ID: 20020197
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.